Mitral Valve Prolapse (MVP) is a prevalent cardiovascular condition characterized by an abnormal closure of the mitral valve, the valve situated between the heart's left atrium and ventricle. In MVP, the valve's leaflets exhibit an unusual bulging or backward collapse into the atrium, leading to blood regurgitation. While some individuals with MVP remain asymptomatic, others may present with symptoms such as chest discomfort, palpitations, or persistent fatigue. The precise etiology of MVP is often elusive, although it can be linked to certain connective tissue disorders. Echocardiography is the primary diagnostic tool for evaluating MVP, enabling a detailed assessment of the mitral valve's structure and functionality. Treatment is generally unnecessary for those without symptomatic manifestations, but individuals with severe cases might be advised to undergo medication therapy. In rare instances, surgical intervention may be considered to repair or replace the affected valve. Regular monitoring and consistent communication with healthcare providers are crucial for the effective management of Mitral Valve Prolapse.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : Not So Idiopathic After All: Genotype, Phenotype and IL-1 Blockade Response Converge in Recurrent Pericarditis
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Beyond the Heart in Cardiovascular Magnetic Resonance Imaging: Prevalence and Clinical Significance of Incidental Extracardiac Findings
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Cardiovascular mortality in colon cancer a patient characteristics analysis: Population-based study
Nouf, KAU, Saudi Arabia
Title : Improving Screening and Treatment of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction: A Two-Cycle Quality Improvement Project
Danish Malik, University Hospitals Dorset NHS Foundation Trust, United Kingdom